Delivery and Specificity of CRISPR-Cas9 Genome Editing Technologies for Human Gene Therapy.

@article{Gori2015DeliveryAS,
  title={Delivery and Specificity of CRISPR-Cas9 Genome Editing Technologies for Human Gene Therapy.},
  author={Jennifer L. Gori and Patrick D. Hsu and Morgan L. Maeder and Shen Shen and G. Grant Welstead and David A. Bumcrot},
  journal={Human gene therapy},
  year={2015},
  volume={26 7},
  pages={
          443-51
        }
}
Genome editing using the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated 9 (Cas9) technology is revolutionizing the study of gene function and likely will give rise to an entire new class of therapeutics for a wide range of diseases. Achieving this goal requires not only characterization of the technology for efficacy and specificity but also optimization of its delivery to the target cells for each disease indication. In this review we survey the various… 

Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery

Recent methods for increasing the activity and accuracy of Cas9 and assessing the extent of off-target cleavage events are reviewed.

Advances in therapeutic application of CRISPR-Cas9.

The recent therapeutic application of CRISPR-Cas9 in various diseases, including hematologic diseases, infectious diseases and malignant tumor is reviewed.

Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity.

The evolution of CRISPR/Cas9 and their cousins: hope or hype?

An overview of CRISPR nucleases (Cas9 or Cpf1) with particular emphasis on human genome modification and compare their advantages and limitations is presented.

The evolution of CRISPR/Cas9 and their cousins: hope or hype?

An overview of CRISPR nucleases (Cas9 or Cpf1) with particular emphasis on human genome modification and compare their advantages and limitations is presented.

Gene Delivery Technologies for Efficient Genome Editing: Applications in Gene Therapy

This chapter will summarize the different ways to deliver SNs and donor DNA and suggest ways to improve their efficiency and safety before translation into clinic.

Delivery of CRISPR/Cas9 for therapeutic genome editing

The modes of CRisPR/Cas9 delivery, the barriers to the delivery process and the application of CRISPR/ Cas9 system for the treatment of genetic disorders are discussed and several representative types of non‐viral vectors are highlighted.

CRISPR/Cas System and Factors Affecting Its Precision and Efficiency

This work focused on factors affecting the genome-editing efficiency and precision of CRISPR/Cas system along with its defense-mechanism, orthologues, and applications.

CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy

Recent progress of the CRISPR-Cas technology in editing host genes as an antiviral strategy is summarized.

In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.

This Topical Review will highlight recent developments in CRISPR delivery, and present hurdles that still need to be overcome to achieve effective in vivo editing.
...

References

SHOWING 1-10 OF 101 REFERENCES

Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity

Efficient CRISPR/Cas9-Mediated Genome Editing in Mice by Zygote Electroporation of Nuclease

This work employed electroporation as a means to deliver the CRISPR/Cas9 components into mouse zygotes and recovered live mice with targeted nonhomologous end joining and homology-directed repair mutations with high efficiency.

Genetic screens: CRISPR screening from both ways

Two related tools called CRISpri and CRISPRa to repress or induce, respectively, individual transcripts with minimal off-target effects are reported, which provide complementary biological insights through both lossand gain-of-function genetic screens.

CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox.

A versatile set of plasmids and vectors derived from adeno-associated virus that allow robust and specific delivery of the two essential CRISPR components - Cas9 and chimeric g(uide)RNA - either alone or in combination are reported, and original evidence that AAV/CRISPR vectors can be exploited for gene engineering in vivo is provided.

Repurposing CRISPR/Cas9 for in situ functional assays

These results establish Cas9 genome editing as a powerful and practical approach for positive in situ genetic screens.

In vivo genome editing using Staphylococcus aureus Cas9

Six smaller Cas9 orthologues are characterized and it is shown that Cas9 from Staphylococcus aureus (SaCas9) can edit the genome with efficiencies similar to those of SpCas9, while being more than 1 kilobase shorter.

Multiplex Genome Engineering Using CRISPR/Cas Systems

Two different type II CRISPR/Cas systems are engineered and it is demonstrated that Cas9 nucleases can be directed by short RNAs to induce precise cleavage at endogenous genomic loci in human and mouse cells, demonstrating easy programmability and wide applicability of the RNA-guided nuclease technology.

RNA-Guided Human Genome Engineering via Cas9

The type II bacterial CRISPR system is engineer to function with custom guide RNA (gRNA) in human cells to establish an RNA-guided editing tool for facile, robust, and multiplexable human genome engineering.
...